Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by SPCEO1on Jul 13, 2021 9:54am
316 Views
Post# 33535269

Question for those complaining about

Question for those complaining aboutthose of us who complain about the substandard efforts, or in some cases just the substandard results, of TH regarding marketing the stock to investors.

Since the complainers about the complainers seem to come from the scientific arena, I thought this question might help you understand where we are coming from on the business/investing side of the equation.

What would you think if TH produced great scientific results but refused to publish them or speak at conferences about them? Or what if they presented at conferences and published their work in scientific journals but their presentations were much weaker than what you had become accustomed to from others using the same venues? I imagine you would think that to be foolish and would be quite frustrated by the company missing out on getting the notoriety their work deserved. 

For us on the investment side of the equation, it seems equally foolish to not fully inform the various types of investors who are constantly on the lookout for stocks with intriguing and potentially very profitable opportunities. OR to try to do so but continuously fail to pull it off when so many other companies seem to be having very little difficulty doing the same thing with worse fundamentals and business outlooks.

Does that help explain our frustration??
<< Previous
Bullboard Posts
Next >>